Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
66. |
ECCT/20/12/03 | CALINA STUDY A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria. Study number: CCOA566B2307 |
Principal Investigator(s) 1. Benhards Ragama Ogutu Site(s) in Kenya KEMRI-Centre for Clinical Research (CCR) |
View |
67. |
ECCT/21/02/04 | GASTROSAM GASTROSAM Gastroenteritis: Rehydration of children with severe acute malnutrition |
Principal Investigator(s) 1. Professor Kathryn Maitland Site(s) in Kenya Kilifi County Hospital |
View |
68. |
ECCT/21/05/03 | Adapt Out COVID Adaptive Platform Treatment trial for Outpatients with COVID-19 |
Principal Investigator(s) 1. Kawango Agot Site(s) in Kenya 1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county) 2. KEMRI WALTER REED (Kericho county) 3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 4. Kenya Medical Research Institute (Kisumu county) |
View |
69. |
ECCT/21/05/05 | The “EMPATHY” Trial A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. |
Principal Investigator(s) 1. DR LUCAS OTIENO TINA 2. Dr. Bernhards Ragama Ogutu 3. Dr Deborah Chepngeno Langat 4. Dr Videlis Nduba Nduba 5. Dr Janet Oyieko Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county) 3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county) 4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county) |
View |
70. |
ECCT/21/05/06 | VAC52150EBL2010 ;Phase 2 An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen |
Principal Investigator(s) 1. Prof. Omu Anzala Omu Anzala Site(s) in Kenya KAVI-institute of Clinical Research |
View |